Clinical Study

Efficacy and Safety of CVT-E002, a Proprietary Extract of Panax quinquefolius in the Prevention of Respiratory Infections in Influenza-Vaccinated Community-Dwelling Adults: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial

Table 3

Between group comparison in laboratory-confirmed infections for different viruses.

PlaceboCVT-E002-400CVT-E002-800 valuea
253249246

Rhinovirus4980.338
Coronavirus OC 4367110.375
Coronavirus NL-63130.164
Coronavirus 229-E340.150
RSV8930.214
Parainfluenza3240.703
Influenza-A2310.609
Influenza-B10.360
Adenovirus10.376
Meta-pneumonia420.131

aBetween-group comparisons made using chi-square test for comparing proportions, all differences were found to be nonsignificant.